7r9y

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (09:08, 17 October 2024) (edit) (undo)
 
(2 intermediate revisions not shown.)
Line 1: Line 1:
==Structure of PIK3CA with covalent inhibitor 22==
==Structure of PIK3CA with covalent inhibitor 22==
-
<StructureSection load='7r9y' size='340' side='right'caption='[[7r9y]]' scene=''>
+
<StructureSection load='7r9y' size='340' side='right'caption='[[7r9y]], [[Resolution|resolution]] 2.85&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7R9Y OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7R9Y FirstGlance]. <br>
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7R9Y OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7R9Y FirstGlance]. <br>
-
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7r9y FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7r9y OCA], [https://pdbe.org/7r9y PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7r9y RCSB], [https://www.ebi.ac.uk/pdbsum/7r9y PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7r9y ProSAT]</span></td></tr>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.85&#8491;</td></tr>
 +
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=2IX:N-[2-(4-{4-[2-amino-4-(difluoromethyl)pyrimidin-5-yl]-6-(morpholin-4-yl)-1,3,5-triazin-2-yl}piperazin-1-yl)-2-oxoethyl]-N-methyl-1-(prop-2-enoyl)piperidine-4-carboxamide'>2IX</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7r9y FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7r9y OCA], [https://pdbe.org/7r9y PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7r9y RCSB], [https://www.ebi.ac.uk/pdbsum/7r9y PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7r9y ProSAT]</span></td></tr>
</table>
</table>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Covalent protein kinase inhibitors exploit currently noncatalytic cysteines in the adenosine 5'-triphosphate (ATP)-binding site via electrophiles directly appended to a reversible-inhibitor scaffold. Here, we delineate a path to target solvent-exposed cysteines at a distance &gt;10 A from an ATP-site-directed core module and produce potent covalent phosphoinositide 3-kinase alpha (PI3Kalpha) inhibitors. First, reactive warheads are used to reach out to Cys862 on PI3Kalpha, and second, enones are replaced with druglike warheads while linkers are optimized. The systematic investigation of intrinsic warhead reactivity (kchem), rate of covalent bond formation and proximity (kinact and reaction space volume Vr), and integration of structure data, kinetic and structural modeling, led to the guided identification of high-quality, covalent chemical probes. A novel stochastic approach provided direct access to the calculation of overall reaction rates as a function of kchem, kinact, Ki, and Vr, which was validated with compounds with varied linker lengths. X-ray crystallography, protein mass spectrometry (MS), and NanoBRET assays confirmed covalent bond formation of the acrylamide warhead and Cys862. In rat liver microsomes, compounds 19 and 22 outperformed the rapidly metabolized CNX-1351, the only known PI3Kalpha irreversible inhibitor. Washout experiments in cancer cell lines with mutated, constitutively activated PI3Kalpha showed a long-lasting inhibition of PI3Kalpha. In SKOV3 cells, compounds 19 and 22 revealed PI3Kbeta-dependent signaling, which was sensitive to TGX221. Compounds 19 and 22 thus qualify as specific chemical probes to explore PI3Kalpha-selective signaling branches. The proposed approach is generally suited to develop covalent tools targeting distal, unexplored Cys residues in biologically active enzymes.
 +
 +
Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kalpha.,Borsari C, Keles E, McPhail JA, Schaefer A, Sriramaratnam R, Goch W, Schaefer T, De Pascale M, Bal W, Gstaiger M, Burke JE, Wymann MP J Am Chem Soc. 2022 Mar 30. doi: 10.1021/jacs.1c13568. PMID:35353516<ref>PMID:35353516</ref>
 +
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
<div class="pdbe-citations 7r9y" style="background-color:#fffaf0;"></div>
 +
 +
==See Also==
 +
*[[Phosphoinositide 3-kinase 3D structures|Phosphoinositide 3-kinase 3D structures]]
 +
== References ==
 +
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>

Current revision

Structure of PIK3CA with covalent inhibitor 22

PDB ID 7r9y

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools